Oct 23, 2026 · 1h 4m
Listen from 34:07
Listen at 34:07
AI challenges biotech’s old company model
Episode 200 - October 23, 2026
The episode connects weak market sentiment and difficult financing with a deeper question: whether AI will change how biotech companies are built and led.
- 1Biotech’s bearish market reflects valuation pressure, trading dynamics, and the sector’s persistent difficulty turning science into durable returns.
- 2Silence Therapeutics’ acquisition illustrates how biotech leadership must navigate scientific risk, company-building, and uncertain outcomes.
- 3AI could redistribute biotech’s core functions, allowing smaller teams to design drugs, choose targets, and access development infrastructure externally.
Don't miss
Ali Mortazavi argues that AI and distributed development tools could make the conventional definition of a biotech company obsolete.
The brief
Biotech Hangout marks its 200th episode by looking back on five years of industry debate, then turning to a sector facing weak sentiment and persistent market-structure pressures.
The panel uses Moderna’s stock decline, the “biotech woodchipper,” and investor sentiment to examine how valuation, trading dynamics, and the difficulty of drug development shape the market.
Ali Mortazavi recounts Silence Therapeutics’ long path through RNAi challenges to its acquisition by Merck KGaA, offering a compressed case study in biotech company-building.
The conversation asks whether AI will reduce the need for traditional biotech CEOs, as software, distributed teams, and external partners make the boundaries of a biotech company less clear.
Alongside M&A, China deals, public-facing executives, and scientific controversies, the panel considers what biotech might look like when the show reaches its 2031 horizon.
What was said on this episode
58 statements · 37 positive · 15 negative · 4 mixed · 2 neutral
Moderna’s valuation reflected substantial market expectations for its cancer vaccine.
“we're sitting here with revenue of what 2.2 2.3 billion dollars this year and therefore the amount of hope that's been pumped into this um story by the market um for the cancer vaccine is incredible”
Listen at 6:42
Market expectations for Moderna’s cancer vaccine became exceptionally high.
“the amount of hope that's been pumped into this um story by the market um for the cancer vaccine is incredible”
Listen at 6:48
Moderna’s valuation had reached a level requiring nearly perfect results.
“it was getting to a point where you needed absolute perfection”
Listen at 7:40
Moderna’s valuation had reached a level requiring near-perfect execution.
“you needed absolute perfection”
Listen at 7:41
Investors were seeking reasons to take profits after Moderna’s large increase.
“all that's going on here is people have tried to find a reason to to take profit for something that's gone up i don't know 200 300 400 depending where you measure it from”
Listen at 9:29
Moderna’s stock remained above levels implied by the known trial success.
“this is clearly above what people thought this could do”
Listen at 10:46
Moderna’s stock price had moved above expectations before the pullback.
“this is clearly above what people thought this could do in the context of if you take a step out and look at it from a wider lens as opposed to what it was trading at the day before”
Listen at 10:46
Moderna’s cancer vaccine is more likely to become a major commercial product after the data.
“is this going to be a big seller for the companies clearly today now that we know the data it's a stronger yes”
Listen at 11:13
The biotech market is currently bearish.
“It's a bearish biotech tape.”
Listen at 12:12
Biotech fundamentals remain strong despite weak market performance.
“the fundamentals still seem really, really strong”
Listen at 13:20
Biotech is becoming more profitable, revenue-generating, and attractive to generalist investors.
“the sector itself is incredibly well positioned, increasingly profitable, increasingly revenue generating, increasingly appealing to the things that generalists really do care about”
Listen at 13:32
- Matt Glineon Dario or AnthropicPositive14:53
Dario or Anthropic will eventually enter or transform pharmaceuticals.
“Dario or Anthropic would eventually experience pharma”
Listen at 14:53
Technical trading dynamics largely drove Moderna’s price movement rather than fundamental value.
“it was entirely technical explanation for what had happened that had relatively little to do with either Moderna's actual value or anybody else's actual value”
Listen at 16:21
Fund de-grossing may be materially affecting biotech sector performance.
“this is the first time in the history of the industry that we've ever talked about this degrossing, having a very real and maybe tangible impact on the sector”
Listen at 18:09
Structural trading dynamics may currently affect biotech valuations more than fundamentals.
“the structural issues are potentially more of an impact than the fundamental issues”
Listen at 19:01
The biotech market will resume a healthy trajectory after the difficult quarter.
“I'm of the sentiment that right now we've got more things that are working and it's been a tough quarter, but I'm predicting that we'll resume with kind of a healthy market.”
Listen at 22:26
The biotech market will resume a healthier trajectory after current difficulties.
“I'm predicting that we'll resume with kind of a healthy market”
Listen at 22:33
Biotech sector fundamentals are exceptionally strong.
“The fundamentals of the sector are phenomenal.”
Listen at 24:41
Biotech sector fundamentals are exceptionally strong despite external volatility.
“The fundamentals of the sector are phenomenal”
Listen at 24:41
Pharmaceutical companies are replenishing pipelines ahead of an unusually large patent-expiration wave.
“pharma companies are continuing to replenish their pipelines ahead of an unprecedented patent cliff”
Listen at 26:31
Silence’s switch to polycythemia vera was an exceptionally good corporate decision.
“someone in silence, i don't know who, decided to switch to PV. And honestly, that's probably one of the best, best biotech corporate decisions ever made.”
Listen at 34:07
- Ali Mortazavion platform biotech companiesNegative35:30
Platform biotech companies may function like hedge funds in disguise.
“biotechs, especially platform biotechs, are actually hedge funds in disguise”
Listen at 35:30
Day-to-day teams contribute more to Roivant than its CEO does.
“the people around me do so much more good for Roy Vint than I do every day”
Listen at 36:12
- Matt Glineon biotech industryNeutral36:22
Biotech progress is primarily driven by people doing day-to-day work.
“it's an industry that's a game of inches propelled by the people on the ground doing the work”
Listen at 36:22
Greater public understanding and authenticity would benefit the biotech industry.
“our industry is so misunderstood and sadly so hated by the general public that if it was better understood and we were more authentic and you know, showed the people behind it. That would be a good thing for all of us.”
Listen at 39:18
Public social-media discussion of Abivax greatly exceeds private investor discussion.
“the noise about Abivax on this platform. outpaces the noise about Abivax in the other rooms that are not as public that I'm in, like 100 to 1.”
Listen at 42:19
Abivax presented additional encouraging academic-conference data.
“ABOVAX had some more data at an academic conference this week that looked good.”
Listen at 42:58
Many biotech investors own options rather than underlying stocks.
“too many people own options and not stocks”
Listen at 44:43
The XBI’s rise indicates an exceptionally strong biotech market year.
“the XBI started the year at 108, it's at 150. By any measure, this is one of the best biotech markets of all time”
Listen at 45:01
Options speculation around acquisition timing can push Abivax’s stock out of control.
“a stock like... avivax gets totally out of control because everyone's betting on which month is it going to be acquired by”
Listen at 45:25
Tango reported highly positive pancreatic-cancer data in refractory patients.
“we just saw game-changing data, 82% response rate and 88% non-progression rate at nine months in very refractory third and fourth line pancreatic cancer patients”
Listen at 49:03
Tango’s PRMT5 inhibitor showed an 82% response rate and 88% nine-month non-progression rate.
“82% response rate and 88% non-progression rate at nine months in very refractory third and fourth line pancreatic cancer patients”
Listen at 49:06
Tango’s pancreatic-cancer data ranks among the strongest oncology data Eric has seen.
“this is perhaps some of the best data I've ever seen covering the oncology space for many, many years”
Listen at 49:17
Tango’s share-price decline is temporary within a positive long-term trajectory.
“this is a short-term blip on an otherwise long-term positive trajectory”
Listen at 49:50
The Treasury proposal could significantly discourage China-related biotech venture investment and company formation.
“the treasury proposal which has an open public hearing period but it is pretty onerous in the current language of what that would mean to chill the venture investment and new codes started from China.”
Listen at 51:25
Sabatini won a $6 million judgment after defamatory claims harmed his career and income.
“Sabatini won the judgment $6 million, which is a pretty sizable settlement over a five-year period in the fact that her defamatory claims as what it was ruled hurt his career, hurt his money-making income.”
Listen at 52:48
Institutions should avoid public accusations before allegations are proven.
“these institutions should be careful about what they say about people before things are proven”
Listen at 54:15
Higher launch prices have helped biotech companies become profitable and more investable.
“that's actually changed quite dramatically thanks to Much higher launch prices, companies vaulting into profitability in the sector”
Listen at 55:11
Biotech innovation will progress strongly if drug-pricing rhetoric does not interfere.
“as long as we don't have new drug pricing rhetoric getting in the way of the sector, it's just going to be an incredible ride.”
Listen at 55:33
Biotech innovation will continue producing major advances absent restrictive drug-pricing rhetoric.
“it's just going to be an incredible ride”
Listen at 55:38
Oncology will make substantial progress against difficult diseases, including GBM.
“i think that oncology would be again solving the diseases that they are difficult gbm potentially some of the smaller indications i think we'll see a lot of progress there”
Listen at 56:14
Oncology will make substantial progress against difficult diseases including GBM and smaller indications.
“oncology would be again solving the diseases that they are difficult gbm potentially some of the smaller indications”
Listen at 56:15
Cancer treatment will increasingly enable patients to live with cancer rather than die from it.
“a lot of people living with cancer as opposed to dying of it”
Listen at 56:26
Neurological diseases will eventually become treatable through major neuroscience advances.
“neuroscience i'm really looking forward to neurological diseases being finally cracked open and treated”
Listen at 56:30
“AI is not going to live up to the current hype fully.”
Listen at 57:44
“AI is not going to live up to the current hype fully”
Listen at 57:44
Genetic medicines will achieve commercial success.
“I'm at least hopeful that genetic medicines are actually going to be successful, commercially successful”
Listen at 58:38
Genetic medicines will achieve commercial success.
“genetic medicines are actually going to be successful, commercially successful”
Listen at 58:39
Commercial genetic-medicine success will first emerge in AATD and Beam’s program.
“I think it's going to happen first with AATD and Beam's program.”
Listen at 58:54
“I hope we're talking about the meteoric rise of Roivant”
Listen at 59:21
“I hope we're talking about the meteoric rise of Roivant.”
Listen at 59:21
- Matt Glineon AI in biotechPositive59:27
AI will transform biotech substantially by 2031.
“AI is about to change biotech in an enormous way in 2031.”
Listen at 59:27
- Matt Glineon AI in biotechPositive59:27
AI will transform biotech substantially by 2031.
“AI is about to change biotech in an enormous way in 2031”
Listen at 59:27
Brain-shuttle technologies will revolutionize neuroscience.
“brain shuttle technologies are going to revolutionize neuroscience”
Listen at 1:00:38
Degrader drugs will become the next major medicine class.
“I think degraders are going to be the next mega class of medicines.”
Listen at 1:01:00
- Ali Mortazavion biotech infrastructure in the AI eraMixed1:01:48
AI is challenging biotech’s traditional infrastructure and organizational definition.
“the whole of biotech infrastructure and what is a biotech is at play”
Listen at 1:01:48
- Ali Mortazavion AI-enabled clinical trialsPositive1:02:24
AI-enabled biotech infrastructure may make clinical trials broadly accessible.
“almost anyone can do a clinical trial”
Listen at 1:02:24
- Ali Mortazavion clinical operations in biotechPositive1:02:41
Clinical operations may become biotech’s key strategic asset.
“the ClinOps is really the key, I think the key... asset, really, in biotech.”
Listen at 1:02:41
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.